
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio Inc demonstrates a robust potential for growth, primarily driven by its innovative pipeline that addresses chronic and acute neurodegenerative diseases, particularly through its lead product, Buntanetap. Recent interim results from its clinical trials indicate a reduction in sAPP levels, which promises a significant opportunity for disease modification in Alzheimer's and Parkinson's patients, with plans to initiate a Phase 2 trial in late 2025. Furthermore, the company has established alignment with the FDA regarding the new drug application process, enhancing confidence in its developmental strategies and potential market entry, contingent on favorable trial results.
Bears say
Annovis Bio Inc faces significant financing risks, particularly as it operates with a very modest cash runway, which may necessitate dilutive capital-raising activities. The company's pipeline targets challenging neurodegenerative diseases like Alzheimer's and Parkinson's, which historically present high rates of clinical trial failures due to efficacy and safety concerns. Furthermore, the potential lack of FDA approval for product filings, as well as anticipated competition and pricing pressures, could hinder any future commercial success.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares